Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor D Bandeira

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Journal of Affective Disorders|December 2, 2019
Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority studyFernanda S Correia-Melo, Gustavo C Leal, Flávia Vieira, et al.
Journal of Affective Disorders|March 5, 2023
Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot studyGustavo C Leal, Breno Souza-Marques, Rodrigo P Mello, et al.
Neuroscience and Biobehavioral Reviews|June 10, 2026
Global prevalence and disability burden of brain disorders: Impact of neurological, mental, and substance use disordersMohammad Ali Salehinejad, Ali Fathi Jouzdani, Igor D Bandeira, et al.
Medicine|September 22, 2018
Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trialFernanda S Correia-Melo, Gustavo C Leal, Michelle S Carvalho, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Journal of Affective Disorders|December 2, 2019
Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority studyFernanda S Correia-Melo, Gustavo C Leal, Flávia Vieira, et al.
Journal of Affective Disorders|March 5, 2023
Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot studyGustavo C Leal, Breno Souza-Marques, Rodrigo P Mello, et al.
Neuroscience and Biobehavioral Reviews|June 10, 2026
Global prevalence and disability burden of brain disorders: Impact of neurological, mental, and substance use disordersMohammad Ali Salehinejad, Ali Fathi Jouzdani, Igor D Bandeira, et al.
Medicine|September 22, 2018
Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trialFernanda S Correia-Melo, Gustavo C Leal, Michelle S Carvalho, et al.
Pageof 4